Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 8,050.00
-160.00 (-1.95%)
Last updated: May 7, 2026, 2:11 PM KST
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 96.27 billion as of May 7, 2026. Its market cap has decreased by -34.34% in one year.
Market Cap
96.27B
Enterprise Value
185.31B
Revenue
19.02B
Ranking
n/a
PE Ratio
35.22
Stock Price
8,050.00
Market Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 96.27B, a decrease of -73.30%. That is a compound annual growth rate of -23.43%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 7, 2026 | 96.27B | -37.67% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
| May 28, 2021 | 360.58B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| MedPacto | 179.94B |
| Macrogen | 175.85B |
| Vaxcell-Bio Therapeutics | 168.38B |
| ENCell | 167.88B |
| Amicogen | 125.27B |
| iNtRON Biotechnology | 109.86B |
| IMB Dx | 100.09B |
| Oncocross | 100.01B |